Business
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer
About this update from Aclarion, Inc.
[{"type":"text","content":"LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation\n \nNorway is a single-payer national health insurance system\n \nLIFEHAB is targeting enrollment to begin in the second quarter of 2024\n \nBROOMFIELD, CO - (NewMediaWire) - April 25, 2024 - Aclarion, Inc., (\"Aclarion\" or the \"Company\") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution will be utilized in the upcoming LIFEHAB Trial in Norway. The randomized controlled trial studying 202 patients with low back pain greater than 1 year in duration will compare treatment outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation.\n\"Diagnosing the source of chronic low back pain is a significant challenge for clinicians,\" said Dr. Ansgar Espeland. \"At Haukeland University Hospital, our radiology team has participated in numerous clinical trials seeking to better understand the linkage between the diagnosis and treatment of chronic low back pain. The LIFEHAB Trial is our latest effort to advance scientific understanding of chronic low back pain. The trial is headed by orthopedic surgeon Dr. Christian Hellum at Oslo University Hospital, Ulleval in cooperation with Dr. Sverre Mjones, Akershus University Hospital. We are pleased to have Nociscan as part of the trial, which we expect may provide important insights not available without Nociscan. LIFEHAB will evaluate treatment outcomes for 202 patients, comparing surgical fusion with multidisciplinary rehabilitation, a comparison we believe will help improve patient outcomes for this complicated ailment.\" \nThe Company believes the LIFEHAB trial combined with other compelling evidence, marks an important step toward achieving successful reimbursement in a single-payer national health insurance system like Norway's, which was adopted in 1966.\nGlobally, 266 million people suffer from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifie...